A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
Completed
Hoffmann-La Roche
N/A
1969-12-31
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis
in patients who have been treated for this condition in the past. This study also examines
the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Completed
Hoffmann-La Roche
Phase 3
1997-01-01
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients
with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance
level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the
pharmacokinetics of ganciclovir following administration of RS-79070 in the target
population.
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
2000-08-01
Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The
purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA
for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in
people with HIV.
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
Completed
National Cancer Institute (NCI)
Phase 3
2001-01-01
RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in
preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing
cytomegalovirus.
PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works
in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
